PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32621159-0	2020	Neuroprotective effects of metformin on traumatic brain injury in rats is associated with the AMP-activated protein kinase signaling pathway.	Metformin	27-36	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	94-122	
32621159-1	2020	Metformin is an activator of AMP-activated protein kinase (AMPK).	Metformin	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	29-57	
32621159-1	2020	Metformin is an activator of AMP-activated protein kinase (AMPK).	Metformin	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	59-63	
32621159-12	2020	Furthermore, the p-AMPK/AMPK ratio was increased by metformin administration compare to TBI or Vehicle groups (p < 0.0001).	Metformin	52-61	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	19-23	
32621159-12	2020	Furthermore, the p-AMPK/AMPK ratio was increased by metformin administration compare to TBI or Vehicle groups (p < 0.0001).	Metformin	52-61	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	24-28	
32621159-13	2020	Inhibition of AMPK by compound C abolished Metformin neuroprotective effects (P < 0.05 compared to Met 200 group).	Metformin	43-52	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	14-18	
32621159-14	2020	This study suggests that metformin inhibits TBI-mediated secondary injury via phosphorylation of AMPK and improves neurobehavioral function following TBI, which provides a potential therapeutic opportunity in the treatment of TBI.	Metformin	25-34	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	97-101